

# Bulk Anti-Human CD2 (LO-CD2a) In Vivo Antibody

**Bulk anti-Human CD2 In Vivo Antibody (LO-CD2a)**

## Product Benefits:

ichorbio's bulk anti-Human CD2 Antibody (LO-CD2a) is manufactured in a cGMP compliant, ISO Quality Standard 9001:2015 facility.

## Target:

CD2

## Other Names:

BTI-322, CD2, CD2 molecule, T11, SRBC, LFA-2, T-cell surface antigen CD2, LFA-3 receptor, rosette receptor, erythrocyte receptor, lymphocyte-function antigen-2, T-cell surface antigen T11/Leu-5, CD2 antigen (p50), sheep red blood cell receptor

## Clone:

LO-CD2a

## Size:

ichorbio's anti-Human CD2 antibody is available in the following bulk sizes: 5mg, 25mg, 50mg and 100mg. ichorbio regularly manufactures multi-gram amounts of our anti-CD2 clone LO-CD2a - please contact us for pricing.

## Isotype:

Rat IgG2b kappa

## Host:

Rat

## Species Reactivity:

Human

## Specificity:

Anti-CD2 antibody (clone LO-CD2a) activity is directed against human CD2.

## Purification Method:

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

**Antigen Distribution:**

CD2 is expressed on all mature human T cells, most thymocytes, NK cells and a small proportion of bone marrow cells.

**Background:**

LO-CD2a strongly inhibits mixed lymphocyte culture (MLC) 3 and induces T cell apoptosis. Additionally, LO-CD2a does not induce proliferation of resting T cells, and inhibits T cell proliferation induced by OKT3 antibody, induces very low levels of cytokine release, and also inhibits cytokine production induced by OKT3, LO-CD2a strongly inhibits proliferation of peripheral blood mononuclear cells stimulated with soluble OKT3, and induces human T cell hyporesponsiveness. Adding LO-CD2a to a primary MLC inhibits the T cell proliferation response and has a subsequent inhibitory effect on the secondary immune response, thereby blocking primary and memory alloantigen proliferative responses. The human T cell hyporesponsiveness in the secondary MLC is restricted to alloantigens and occurs both in the absence of antibody and after cell surface re-expression of CD2.

**Immunogen:**

LO-CD2a was developed as an immunosuppressive agent for use in organ allotransplantation. LO-CD2a was produced by immunizing a LOU/C rat with purified human T lymphocytes and fusing the splenocytes with the non-secreting rat fusion cell line IR983F, resulting in a rat IgG2b mAb of the IgK-1a allotype.

**Concentration:**

>2.0 mg/ml

**Formulation:**

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added. BSA and azide free

**Purity:**

>95% by SDS-PAGE and HPLC

>98% by SDS-PAGE and HPLC

**Endotoxin:**

? 1.0 EU/mg as determined by the LAL method

? 0.75 EU/mg as determined by the LAL method

**Aggregation:**

Aggregation level ? 5%

Aggregation level ? 1%

**Storage:**



This antibody is stable for at least 4 weeks when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at – 20°C or -80°C. Avoid repeated freeze thaw cycles.

**Applications:**

ELISA, Functional Assays, Flow Cytometry

**Application Notes:**

Each investigator should determine their own optimal working dilution for specific applications.

**Use:**

Products are for research use only.